MDXH
MDxHealth SA ADRNASDAQHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$41.09M
P/E Ratio
—
EPS
$-0.65
Beta
-510468.06
52W High
$5.33
52W Low
$0.68
50-Day MA
$2.15
200-Day MA
$3.32
Dividend Yield
—
Profit Margin
-29.90%
Forward P/E
27.70
PEG Ratio
—
About MDxHealth SA ADR
MDxHealth SA is a pioneering biotechnology company dedicated to advancing precision diagnostics in cancer management, primarily targeting prostate and bladder cancers. Its flagship product, ConfirmMDx for Prostate Cancer, has garnered significant attention for its clinical efficacy and strong market presence. With the increasing emphasis on personalized medicine and the rising demand for targeted cancer therapies, MDxHealth is well-positioned to expand its innovative diagnostic offerings, aiming to meet critical unmet needs in oncology and enhance patient outcomes while pursuing sustainable growth.
Fundamentals
| Revenue (TTM) | $110.97M |
| Gross Profit (TTM) | $70.74M |
| EBITDA | $-10.72M |
| Operating Margin | -26.70% |
| Return on Equity | -2440.00% |
| Return on Assets | -6.38% |
| Revenue/Share (TTM) | $2.18 |
| Book Value | $-0.39 |
| Price-to-Book | 23.64 |
| Price-to-Sales (TTM) | 0.37 |
| EV/Revenue | 0.938 |
| EV/EBITDA | 17.57 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 12.70% |
| Shares Outstanding | $51.37M |
| Float | $36.24M |
| % Insiders | 11.13% |
| % Institutions | 48.69% |
Historical Volatility
HV 10-Day
46.09%
HV 20-Day
51.27%
HV 30-Day
52.66%
HV 60-Day
53.44%
HV Rank
23.4%
Volatility is currently contracting
Analyst Ratings
Consensus ($3.90 target)
6
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026